SKU: DPH97 | Published On: Oct 09 2020 | No. of Pages: 217 | Available Formats
The Global Testosterone Replacement Therapy Market is expected to grow at a high CAGR during the forecasting period (2020-2027).
Testosterone Replacement Therapy Market expected to reach USD 1.3 billion by 2026
Testosterone Replacement Therapy (TRT) or androgen replacement therapy is a type of hormone replacement therapy in which androgens, often testosterone, are replaced.
TRT is an FDA-approved medical treatment for men of any age who have low testosterone, the primary male sex hormone.
The global market for Testosterone Replacement Therapy is estimated to reach USD 1.3 billion by 2026.
Primary market drivers include the rise in the incidence of testosterone deficiency, increase in geriatric population with high risk of testosterone deficiency and increasing awareness about testosterone substitute therapy.
However, the high risk of side effects associated with testosterone replacement therapy will restrain market growth.
Testosterone use is possibly associated with an increased risk of developing cardiovascular disease and prostate cancer.
However, the market is continuing to decline due to strict FDA warnings regarding the use of testosterone drugs.
The global Testosterone Replacement Therapy market report segments the market by product type, by active ingredient, and by region.
Based on product type, the TRT market is segmented into oral, implants, gums/ buccal adhesives, injections, patches, and creams/ gels.
Creams/gels segment accounted for the largest share with approximately 66% as they are available in a semi-solid form and can be applied quickly and removed. Also, they contain an active ingredient which can be applied locally for maximum efficacy.
Based on lines of its active ingredient, the market is divided into five categories: testosterone, testosterone cypionate, testosterone enanthate, testosterone undecanoate, and methyltestosterone.
By Product Type
Oral
Implants
Gums/Buccal Adhesives
Injections
Patches
Creams/Gels
By Active Ingredient Type
Testosterone
Testosterone Cypionate
Testosterone Enanthate
Testosterone Undecanoate
Methyl Testosterone
By Region
Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
North America (The USA, Canada, Mexico)
South America (Brazil, Argentina, Rest of South America)
Rest of the World
Geographically, the market is segmented into five major regions: North America, South America, Europe, Asia Pacific, and RoW.
North America dominates the market for Testosterone Replacement Therapy, with the US being the largest market.
The use of testosterone therapy is widespread in the US, with an estimated 2.3 million American men receiving treatment in 2013.
The report also profiles the following companies in Testosterone Replacement Therapy market – AbbVie, Inc., Allergan plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Mylan N.V., Novartis AG, and Pfizer, Inc.
Visualize the composition of Testosterone Replacement Therapy market across each indication, regarding type and treatment options, highlighting the critical commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the market – level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for crucial Testosterone Replacement Therapy of all major market players
Equipment Suppliers/ Buyers
Service Providers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
Manufacturers
1.1. Research Methodology
1.2. Scope of the Report
2.1. Key Trends & Developments
3.1. Market Drivers
3.1.1. Rise in incidence of testosterone deficiency
3.1.2. Increase in geriatric population with high risk of testosterone deficiency
3.1.3. Increasing awareness about testosterone substitute therapy
3.2. Market Restraint
3.2.1. High risk of side effects associated to testosterone replacement therapy
3.3. Threats and Opportunities
3.4. Porter’s Forces
4.1. By Product Type
4.1.1. Oral Implants
4.1.2. Gums/Buccal Adhesives
4.1.3. Injections
4.1.4. Patches
4.1.5. Creams/Gels
4.2. By Active Ingredient
4.2.1. Testosterone
4.2.2. Testosterone Cypionate
4.2.3. Testosterone Enanthate
4.2.4. Testosterone Undecanoate
4.2.5. Methyl Testosterone
5.1. North America
5.1.1. The USA
5.1.2. Canada
5.1.3. Mexico
5.2. Europe
5.2.1. Germany
5.2.2. France
5.2.3. The UK
5.2.4. Italy
5.2.5. Spain
5.2.6. Rest of Europe
5.3. Asia Pacific
5.3.1. China
5.3.2. Japan
5.3.3. India
5.3.4. Australia
5.3.5. Rest of Asia Pacific
5.4. South America
5.4.1. Brazil
5.4.2. Argentina
5.4.3. Rest of South America
5.5. Rest of the World
6.1. Market Share Analysis
6.2. Mergers and Acquisitions Analysis
6.3. New Product Launches
7.1. AbbVie, Inc.
7.2. Allergan plc
7.3. Bayer AG
7.4. Endo Pharmaceuticals, Inc.
7.5. Eli Lilly and Company
7.6. Kyowa Kirin International Plc
7.7. Mylan N.V.
7.8. Novartis AG
7.9. Pfizer, Inc.
8.1. Sources
8.2. List of Tables
8.3. Expert Panel Validation
8.4. Disclaimer
8.5. Contact Us
Get your FREE SAMPLE PROPOSAL with a single click!